Navigation Links
CardioDynamics BioZ(R) ICG Technology Integrates with General Electric Healthcare's Centricity(R) Electronic Medical Record (EMR) System
Date:8/5/2008

GE Centricity(R) -- Third Largest U.S. Outpatient EMR with Nearly 10%

Market Share

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) impedance cardiography (ICG) technology, today announced that the Company's BioZ(R) Dx now seamlessly integrates with General Electric Healthcare's Centricity(R) electronic medical record (EMR) system.

The Company released this week its latest version of BioZport(R) ICG data management software which includes capabilities to automatically integrate and transfer BioZ(R) ICG data from the BioZ(R) Dx to GE Healthcare's Centricity(R) EMR system. This is a strategic advancement for the Company's flagship product as EMR interface and paperless workflow are increasingly becoming necessities to the outpatient physician when making decisions on new medical technologies. Currently, it is estimated that 24% of U.S. outpatient physicians utilize an EMR system. Medical device to EMR interface capability will continue to grow in importance as U.S. outpatient-based physician use of EMR is forecasted to grow at over 16% per year through 2013.

Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "We are extremely pleased to release our initial BioZ ICG direct EMR interface. EMR is a driving, essential factor in the majority of medical device decisions for early adopter physicians and large physician practices. Interfacing with our long-time partner, GE Healthcare, whose Centricity(R) system has nearly 10% share in our sizable outpatient physician market, is a great accomplishment for our company, customers, prospective customers and investors."

Perry continued, "Our EMR strategy is to partner with the top 10% to 15% of EMR suppliers, who collectively have 80% of U.S. outpatient market share. Allscripts, the second largest outpatient EMR provider, with over 12% market share, is our next planned interface. With increasing penetration rates for both ICG and EMR, interface capability should further accelerate the adoption of ICG and supports our long-term vision that BioZ ICG is present in every physician office that prescribes cardiovascular medicine for heart failure, shortness of breath and high blood pressure patients."

BioZ ICG technology presently resides in approximately one out of every six (16%) cardiology offices as well as one out of every five (20%) outpatient heart failure clinics in the United States with over one million BioZ tests performed annually.

For further information, please contact Emma Brejwo at ebrejwo@cdic.com.

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called BioZ(R) Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ(R) ICG products and medical device electrodes. The Company's BioZ(R) ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company's Web site at http://www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on the BioZ(R) product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2007 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.


'/>"/>
SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
2. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
3. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
4. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
5. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
6. CardioDynamics Provides 2007 Shareholder Meeting Update
7. New Book on the Business of Biotechnology
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. eResearchTechnology Reports Second Quarter 2008 Results
10. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
11. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):